Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SIM 0709

Next Previous
Drug Profile

SIM 0709

Alternative Names: SIM-0709

Latest Information Update: 16 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Simcere Pharmaceutical Group
  • Class Anti-inflammatories; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors; Tumour necrosis factor ligand superfamily member 15 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammatory bowel diseases

Most Recent Events

  • 06 Feb 2026 Simcere plans first-in-human clinical trial for Inflammatory bowel disease in H1 2026.
  • 27 Jan 2026 SIM0 709 licensed to Boehringer Ingelheim excluding Great China
  • 27 Jan 2026 Preclinical trials in Inflammatory bowel diseases in China (SC) prior to January 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top